{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-039843","form_type":"8-K","ticker":"JANX","cik":"0001817713","company_name":"Janux Therapeutics, Inc.","filed_at":"2023-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.407144+00:00","generated_at":"2026-06-12T02:35:24.163938+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Janux Q2 net loss $17.5M; cash $303.3M; Nasdaq compliance regained","bullets":["Net loss of $17.5M for Q2 2023 vs. $16.9M in Q2 2022; R&D expense $14.9M, G&A $6.9M.","Cash, cash equivalents & short-term investments of $303.3M at June 30, 2023; July offering raised ~$60M gross.","PSMA-TRACTr JANX007 Phase 1 data showed meaningful PSA drops with manageable safety/CRS profile.","Nasdaq compliance regained after Ron Barrett, Ph.D. became independent director; matter closed.","Appointed Dr. Zachariah McIver as VP, Clinical Development; he brings >15 years bispecific experience."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-039843","json":"https://secwatch.observer/filing/0000950170-23-039843.json","markdown":"https://secwatch.observer/filing/0000950170-23-039843.md","text":"https://secwatch.observer/filing/0000950170-23-039843.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1817713/000095017023039843/0000950170-23-039843-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1817713/000095017023039843/janx-20230808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T02:35:24.163938+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8f1fccc4806b1d46160e986dbffd612432d76fef","claim":"Janux Therapeutics, Inc. reported the second quarter ended June 30, 2023 results: net income a net loss of $17.5 million.","evidence_excerpt":"Janux Therapeutics, Inc. (the \"Company\") issued a press release announcing its financial results for the three and six months ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1817713/000095017023039843/0000950170-23-039843-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Net income","value":"a net loss of $17.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"b7176b3cbb548409a53ab687143fe2e25a834744","claim":"Janux Therapeutics, Inc. reported financial results for the six months ended June 30, 2023.","evidence_excerpt":"Janux Therapeutics, Inc. (the \"Company\") issued a press release announcing its financial results for the three and six months ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1817713/000095017023039843/0000950170-23-039843-index.htm","confidence":0.8,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the six months ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}